Abstract
Isocitrate dehydrogenase (IDH) is a metabolic enzyme that converts isocitrate to α-ketoglutarate (α-KG). Genetic gain-of-function mutations in IDH1 and IDH2 confer a neomorphic activity that allow reduction of α -KG to (R)-2- hydroxyglutarate, the accumulation of which results in the development of cancers like low grade gliomas and leukemia. After treatment with AG-221 in clinical trials, a first-in-class inhibitor of mutated IDH2, 29 patients with acute myeloid leukemia or myelodysplastic syndrome experience complete remissions and the overall response rate is 59/159 (37%). Thus, IDH mutants have become intriguing targets for cancer therapeutics. In addition to providing a brief summary of IDH mutations, this review describes known inhibitors with potential activities against IDH mutants such as AG-120, AG-221, AG-881 and AGI-6780. The evolving landscape of IDH mutant inhibitors provides us an outlook on the discovery of novel, safer, and more effective cancer treatment strategies.
Keywords: Cancer, drug discovery, IDH1, IDH2, inhibitor, mutant.
Mini-Reviews in Medicinal Chemistry
Title:The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors
Volume: 16 Issue: 16
Author(s): Jiao Chen, Jie Yang and Peng Cao
Affiliation:
Keywords: Cancer, drug discovery, IDH1, IDH2, inhibitor, mutant.
Abstract: Isocitrate dehydrogenase (IDH) is a metabolic enzyme that converts isocitrate to α-ketoglutarate (α-KG). Genetic gain-of-function mutations in IDH1 and IDH2 confer a neomorphic activity that allow reduction of α -KG to (R)-2- hydroxyglutarate, the accumulation of which results in the development of cancers like low grade gliomas and leukemia. After treatment with AG-221 in clinical trials, a first-in-class inhibitor of mutated IDH2, 29 patients with acute myeloid leukemia or myelodysplastic syndrome experience complete remissions and the overall response rate is 59/159 (37%). Thus, IDH mutants have become intriguing targets for cancer therapeutics. In addition to providing a brief summary of IDH mutations, this review describes known inhibitors with potential activities against IDH mutants such as AG-120, AG-221, AG-881 and AGI-6780. The evolving landscape of IDH mutant inhibitors provides us an outlook on the discovery of novel, safer, and more effective cancer treatment strategies.
Export Options
About this article
Cite this article as:
Chen Jiao, Yang Jie and Cao Peng, The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors, Mini-Reviews in Medicinal Chemistry 2016; 16 (16) . https://dx.doi.org/10.2174/1389557516666160609085520
DOI https://dx.doi.org/10.2174/1389557516666160609085520 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma
Current Cancer Drug Targets Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design The University of New Mexico Center for Molecular Discovery
Combinatorial Chemistry & High Throughput Screening Chalcones as Promising Lead Compounds on Cancer Therapy
Current Medicinal Chemistry Editorial (Thematic Issue: Self-Assembled Organic Nanostructures in Medicinal Chemistry: Advances and Applications)
Current Topics in Medicinal Chemistry Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment
Current Medicinal Chemistry PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
Current Pharmaceutical Design Every Cloud Has a Silver Lining: Proneurogenic Effects of Aβ Oligomers and HMGB-1 via Activation of the RAGE-NF-κB Axis
CNS & Neurological Disorders - Drug Targets Quantifying Gp96/Grp94 Complexes Preparations for Vaccines: a Key Step Often Inaccurate
Current Medicinal Chemistry Carbohydrate-Metal Complexes and their Potential as Anticancer Agents
Current Medicinal Chemistry Neuroprotective Role of Hypothermia in Hypoxic-ischemic Brain Injury: Combined Therapies using Estrogen
Current Neuropharmacology Expression of Rab3b in Human Glioma: Influence on Cell Proliferation and Apoptosis
Current Pharmaceutical Design Salen Mn Complexes are Superoxide Dismutase/Catalase Mimetics that Protect the Mitochondria
Current Inorganic Chemistry (Discontinued) Positron Emitting Tracers in Pre-Clinical Drug Development
Current Radiopharmaceuticals Therapeutic Use of Chemokines
Current Pharmaceutical Design Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Lipid based Nanocapsules: A Multitude of Biomedical Applications
Current Pharmaceutical Biotechnology Diagnostic and Therapeutic Applications of Exosome Nanovesicles in Lung Cancer: State-of-The-Art
Anti-Cancer Agents in Medicinal Chemistry Distinguished Photons: A Review of In Vivo Spectral Fluorescence Imaging in Small Animals
Current Pharmaceutical Biotechnology miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry